| 000 | 01818 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250518101542.0 | ||
| 264 | 0 | _c20201119 | |
| 008 | 202011s 0 0 eng d | ||
| 022 | _a1365-2036 | ||
| 024 | 7 |
_a10.1111/apt.15762 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBangma, Amber | |
| 245 | 0 | 0 |
_aPredicted efficacy of a pharmacogenetic passport for inflammatory bowel disease. _h[electronic resource] |
| 260 |
_bAlimentary pharmacology & therapeutics _c06 2020 |
||
| 300 |
_a1105-1115 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aBiomarkers, Pharmacological _xanalysis |
| 650 | 0 | 4 | _aCase-Control Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aInflammatory Bowel Diseases _xdiagnosis |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPharmacogenomic Testing _xmethods |
| 650 | 0 | 4 |
_aPharmacogenomic Variants _xgenetics |
| 650 | 0 | 4 | _aPredictive Value of Tests |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aReproducibility of Results |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aTranscriptome _xdrug effects |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aVoskuil, Michiel D | |
| 700 | 1 | _aUniken Venema, Werna T C | |
| 700 | 1 | _aBrugge, Harm | |
| 700 | 1 | _aHu, Shixian | |
| 700 | 1 | _aLanting, Pauline | |
| 700 | 1 | _aFranke, Lude | |
| 700 | 1 | _aDijkstra, Gerard | |
| 700 | 1 | _aFesten, Eleonora A M | |
| 700 | 1 | _aWeersma, Rinse K | |
| 773 | 0 |
_tAlimentary pharmacology & therapeutics _gvol. 51 _gno. 11 _gp. 1105-1115 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/apt.15762 _zAvailable from publisher's website |
| 999 |
_c30929214 _d30929214 |
||